EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study

Muchandifunga Trust Muchadeyi iD, Shuang Hao iD, Karla Hernandez-Villafuerte iD, Shah Alam Khan iD, Nikolaus Becker iD, Agne Krilaviciute iD, Petra Seibold, Roman Gulati iD, Peter Albers iD, Michael Schlander iD, Mark Clements iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Muchandifunga Trust Muchadeyi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Health Economics, German Cancer Research Centre (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cost-Benefit Analysis, Early Detection of Cancer, Mass Screening. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) represents a significant public health challenge in Germany, with increasing incidence and economic impact. This study assessed the cost‐effectiveness of 10 screening strategies: prostate‐specific antigen‐based risk‐adaptive screening (PSA‐RAS), with or without magnetic resonance imaging (MRI), in men starting at age 45 or 50 and stopping at 60 or 70, digital rectal examination (DRE) for ages 45–75 years, and no screening. Using a well calibrated microsimulation model (Swedish Prostata) from a statutory health insurance perspective, lifetime outcomes were evaluated, including cancer incidence, mortality, overdiagnosis, biopsies, life‐years, and quality‐adjusted life‐years (QALYs) discounted annually at 3%. Cost and utility inputs were derived from the German diagnostic‐related group schedule, fee‐for‐service catalogues, literature, and expert opinion. DRE‐only was the least cost‐effective, yielding high biopsy and overdiagnosis rates with minimal QALY gains. PSA‐RAS reduced overdiagnosis and biopsy rates, with PSA‐RAS (50–60 years) without MRI emerging as the most cost‐efficient strategy, saving approximately €1.2 million per 100,000 men compared with no screening. Extending the PSA‐RAS to 70 years improved its effectiveness in terms of QALYs. PSA‐RAS (50–70) with MRI could become cost‐effective at an increasing willingness to pay threshold or decreasing MRI cost. This study suggests the potential of PSA‐RAS to improve PCa screening in Germany. Incorporating MRI, reducing MRI cost within the screening setting, and extending screening to 70 to align with EU recommendations could improve the cost‐effectiveness of PSA‐RAS with MRI. Future research should explore the integration of MRI with ancillary tests, such as 4K‐score or risk calculators, to reduce MRI use and associated costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCost-Benefit AnalysisEarly Detection of CancerMass ScreeningHumansMaleGermanyMiddle AgedAgedProstate-Specific AntigenQuality-Adjusted Life YearsMagnetic Resonance ImagingDigital Rectal ExaminationBiopsyOverdiagnosisCost-Effectiveness Analysis

Stichwörter der Autor:innen

QALYscost‐effectiveness analysismagnetic resonance imagingorganised screeningprostate cancerprostate‐specific antigen

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Division of Health Economics, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Alfred Weber Institute for Economics (AWI), University of Heidelberg, Heidelberg, Germany.

ORCID-Profile: Muchandifunga Trust Muchadeyi, Shuang Hao, Karla Hernandez-Villafuerte, Shah Alam Khan, Nikolaus Becker, Agne Krilaviciute, Roman Gulati, Peter Albers, Michael Schlander, Mark Clements

Förderung

  • NCI NIH HHS

Zitieren

APA

Muchadeyi, M. T., Hao, S., Hernandez-Villafuerte, K., Khan, S. A., Becker, N., Krilaviciute, A., Seibold, P., Gulati, R., Albers, P., Schlander, M., & Clements, M. (2025). Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study. International Journal of Cancer. https://doi.org/10.1002/ijc.35513

Vancouver

Muchadeyi MT, Hao S, Hernandez-Villafuerte K, Khan SA, Becker N, Krilaviciute A, et al. Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study. International Journal of Cancer. 2025. doi:10.1002/ijc.35513

BibTeX
@article{Muchadeyi2025,
  author = {Muchadeyi, Muchandifunga Trust and Hao, Shuang and Hernandez-Villafuerte, Karla and Khan, Shah Alam and Becker, Nikolaus and Krilaviciute, Agne and Seibold, Petra and Gulati, Roman and Albers, Peter and Schlander, Michael and Clements, Mark},
  title = {Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35513}
}
Kostenlos starten →